RxDoctor Payments Data

Jorge Brothers, MD

Urology · Lubbock, TXNPI 1841232923

Payments from drug & device makers

$12,844in general payments, 2019–2025

Across 477 payments — averaging $26.93 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Boston Scientific$3K
  • Johnson & Johnson$2K
  • Dendreon Pharmaceuticals LLC$2K
  • Astellas Pharma US Inc$932
  • Bayer$756
  • AbbVie$438
  • plus $4K from 34 others

What the payments were for

  • Travel & lodging$1,0758%
  • Food & beverage$11,64091%
  • Education$1291%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$12,844 in reported general payments places this provider in the 75th percentile of 878 urology providers in Texas.

See all urology providers in Texas

Medicare billing

Part B allowed, 2024
$847,073
Medicare patients
534
Services billed
12,978

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
MyrbetriqMirabegron97$92,934
GemtesaVibegron15$13,877
Mirabegron ErMirabegron22$10,704
Estradiol135$10,230
Tamsulosin Hcl571$10,092
Finasteride463$6,442
Testosterone Cypionate94$5,258
Np ThyroidThyroid,pork77$4,742
NitrofurantoinNitrofurantoin Macrocrystal78$4,537
Testosterone22$4,025
ProgesteroneProgesterone, Micronized28$2,642
Potassium Citrate ErPotassium Citrate27$2,290
Fluconazole78$2,189
Oxybutynin Chloride ErOxybutynin Chloride43$1,383
Nitrofurantoin Mono-MacroNitrofurantoin Monohyd/M-Cryst18$1,187

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Astellas Pharma US IncMyrbetriq$932$92,93497 claims
Sumitomo Pharma America, Inc.Gemtesa$319$13,87715 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 75th percentile of 878 urology providers in Texas.

Other urology in Lubbock

See the full list for Texas

Where these figures come from

Is this you, or does something look wrong? →